Is granulomatosis with polyangiitis in Asia different from the West?
Godasi S. R. S. N. K. Naidu
Department of Internal Medicine, Postgraduate Institute of Medical Education and Research, Chandigarh, India
Search for more papers by this authorDurga Prasanna Misra
Department of Clinical Immunology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India
Search for more papers by this authorManish Rathi
Department of Nephrology, Postgraduate Institute of Medical Education and Research, Chandigarh, India
Search for more papers by this authorCorresponding Author
Aman Sharma
Department of Internal Medicine, Postgraduate Institute of Medical Education and Research, Chandigarh, India
Correspondence
Aman Sharma, Department of Internal Medicine, Postgraduate Institute of Medical Education and Research, Chandigarh, India.
Email: [email protected]
Search for more papers by this authorGodasi S. R. S. N. K. Naidu
Department of Internal Medicine, Postgraduate Institute of Medical Education and Research, Chandigarh, India
Search for more papers by this authorDurga Prasanna Misra
Department of Clinical Immunology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India
Search for more papers by this authorManish Rathi
Department of Nephrology, Postgraduate Institute of Medical Education and Research, Chandigarh, India
Search for more papers by this authorCorresponding Author
Aman Sharma
Department of Internal Medicine, Postgraduate Institute of Medical Education and Research, Chandigarh, India
Correspondence
Aman Sharma, Department of Internal Medicine, Postgraduate Institute of Medical Education and Research, Chandigarh, India.
Email: [email protected]
Search for more papers by this authorAbstract
The incidence and clinical features of antineutrophil cytoplasmic antibody (ANCA) associated vasculitis (AAV) have been shown to vary according to geographical areas, with granulomatosis with polyangiitis (GPA) being more common in northern Europe and microscopic polyangiitis (MPA) being more common in Asian countries. The annual incidence of GPA among Asians varies between 0.37/million to 2.1/million population. The prevalence of GPA has been estimated to be 1.94/100 000 in a Chinese population. Polymorphisms in class II major histocompatibility genes and ETS1 proto-oncogene has been shown in Asian patients with GPA. There is a difference in mean age at onset and proteinase 3 (PR3) or myeloperoxidase (MPO) positivity in GPA patients from different Asian countries. Those from India had mean age of 40 years and those from Japan had mean age of 65 years. Sixty percent of GPA patients from China and Japan were MPO ANCA positive while the majority of patients from India and Korea were PR3 positive. Geographical variation with lower frequency of renal involvement in Indian studies and higher frequency in Chinese patients has also been noted. Treatment outcomes have been similar to those reported from other parts of the world. Remission was achieved in about two-thirds of patients while relapses were noted in one-third to half of the patients. Apart from minor differences in the organ systems involved, MPO-ANCA GPA and PR3-ANCA GPA had similar rates of remission and relapses.
CONFLICT OF INTEREST
None.
REFERENCES
- 1Fujimoto S, Watts RA, Kobayashi S, et al. Comparison of the epidemiology of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis between Japan and UK. Rheumatology. 2011; 50: 1916-1920.
- 2Holle JU, Gross WL, Latza U, et al. Improved outcome in 445 patients with Wegener's granulomatosis in a German vasculitis center over four decades. Arthritis Rheum. 2011; 63: 257-266.
- 3Hoffman G, Kerr G, Leavitt R, et al. Wegener's granulomatosis: an analysis of 158 patients. Ann Intern Med. 1992; 116: 488-498.
- 4Stone JH, Wegener's Granulomatosis Etanercept Trial Research Group. Limited versus severe Wegener's granulomatosis: baseline data on patients in the Wegener's granulomatosis etanercept trial. Arthritis Rheum. 2003; 48: 2299-2309.
- 5Mahr A, Katsahian S, Varet H, et al. Revisiting the classification of clinical phenotypes of anti-neutrophil cytoplasmic antibody-associated vasculitis: a cluster analysis. Ann Rheum Dis. 2013; 72: 1003-1010.
- 6Reinhold-Keller E, Beuge N, Latza U, et al. An interdisciplinary approach to the care of patients with Wegener's granulomatosis. Long-term outcome in 155 patients. Arthritis Rheum. 2000; 43: 1021-1032.
- 7Liu X, Cui Y, Li Y, et al. Using inpatient data to estimate the prevalence of Wegener's granulomatosis in China. Intractable Rare Dis Res. 2016; 5: 31-35.
- 8Wu CS, Hsieh CJ, Peng YS, et al. Antineutrophil cytoplasmic antibody-associated vasculitis in Taiwan: A hospital-based study with reference to the population-based National Health Insurance database. J Microbiol Immunol Infect. 2015; 48: 477-482.
- 9Tahghighi F, Moradinejad MH, Aghighi Y, et al. Evaluation of 10-year experience of Wegener's granulomatosis in Iranian children. ISRN Rheumatol. 2013; 2013: 694928.
- 10Bambery P, Sakhuja V, Bhusnurmath SR, et al. Wegener's granulomatosis: clinical experience with eighteen patients. J Assoc Physicians India. 1992; 40: 597-600.
- 11Kumar A, Pandhi A, Menon SK, Sharma SK, Pande JN, Malaviya AN. Wegener's granulomatosis in India: clinical features, treatment and outcome of 25 patients. Indian J Chest Dis Allied Sci. 2001; 43: 197-204.
- 12Kumar A, Dembla G, Abrol A, et al. Clinical profile and long-term outcome of Granulomatosis with Polyangiitis (GPA): a corporate hospital-based study from northern India. Indian J Rheumatol. 2015; 10: 183-188.
10.1016/j.injr.2015.06.001 Google Scholar
- 13Sharma A, Naidu GSRSNK, Rathi M, et al. Clinical features and long term outcomes of 105 granulomatosis with polyangiitis patients: a single centre experience from north India. Int J Rheum Dis. 2018; 21: 278-284.
- 14Handa R, Wali JP, Biswas A, et al. Wegener's granulomatosis – a clinicopathologic study. J Assoc Physic India. 1997; 45: 536-539.
- 15Kim HW, Kim JW, Im CH, et al. The clinicopathologic characteristics of granulomatosis with polyangiitis (Wegener's): a retrospective study of 45 patients in Korea. Mod Rheumatol. 2013; 23: 864-871.
- 16Lyons PA, Rayner TF, Trivedi S, et al. Genetically distinct subsets within ANCA-associated vasculitis. N Engl J Med. 2012; 367: 214-223.
- 17Rahmattulla C, Mooyaart AL, Van Hooven D, et al. Genetic variants in ANCA-associated vasculitis: a meta-analysis. Ann Rheum Dis. 2016; 75: 1687-1692.
- 18Xie G, Roshandel D, Sherva R, et al. Association of granulomatosis with polyangiitis (Wegener's) with HLA-DPB1*04 and SEMA6A gene variants: evidence from genome-wide analysis. Arthritis Rheum. 2013; 65: 2457-2468.
- 19Knight A, Sandin S, Askling J. Risks and relative risks of Wegener's granulomatosis among close relatives of patients with the disease. Arthritis Rheum. 2008; 58: 302-307.
- 20Relle M, Fohr B, Fasola F, et al. Genetics and pathophysiology of granulomatosis with polyangiitis (GPA) and its main autoantigen proteinase 3. Mol Cell Probes. 2016; 30: 366-373.
- 21Luo H, Chen M, Yang R, et al. The association of HLA-DRB1 alleles with antineutrophil cytoplasmic antibody-associated systemic vasculitis in Chinese patients. Hum Immunol. 2011; 72: 422-425.
- 22Wu Z, Wu Q, Xu J, et al. HLA-DPB1 variant rs3117242 is associated with anti-neutrophil cytoplasmic antibody-associated vasculitides in a Han Chinese population. Int J Rheum Dis. 2017; 20: 1009-1015.
- 23Kawasaki A, Yamashita K, Hirano F, et al. Association of ETS1 polymorphism with granulomatosis with polyangiitis and proteinase 3-anti-neutophil cytoplasmic antibody positive vasculitis in a Japanese population. J Hum Genet. 2018; 63: 55-62.
- 24Kawasaki A, Hasebe N, Hidaka M, et al. Protective role of HLA-DRB1*13:02 against microscopic polyangiitis and MPO-ANCA positive vasculitides in a Japanese population: a case-control study. PLoS ONE. 2016; 11: e0154393.
- 25Heckmann M, Holle JU, Arning L, et al. The Wegener's granulomatosis quantitative trait locus on chromosome 6p21.3 as characterised by tagSNP genotyping. Ann Rheum Dis. 2008; 67: 972-979.
- 26Rani L, Minz RW, Sharma A, et al. Predominance of PR3 specific immune response and skewed Th17 vs. T regulatory milieu in active granulomatosis with polyangiitis. Cytokine. 2015; 71: 261-267.
- 27Rani L, Minz RW, Arora A, et al. Serum protein profiling in granulomatosis with polyangiitis using two-dimensional gel electrophoresis along with matrix assisted laser desorption ionization in time of flight mass spectrophotometry. Int J Rheum Dis. 2014; 17: 910-919.
- 28Chen M, Yu F, Zhang Y, et al. Characteristics of Chinese patients with Wegener's granulomatosis with anti-myeloperoxidase autoantibodies. Kidney Int. 2005; 68: 2225-2229.
- 29Ono N, Niiro H, Ueda A, et al. Characteristics of MPO-ANCA-positive granulomatosis with polyangiitis: a retrospective multi-centre study in Japan. Rheumatol Int. 2015; 35: 555-559.
- 30Sada KE, Yamamura M, Harigai M, et al. Classification and characteristics of Japanese patients with antineutrophil cytoplasmic antibody-associated vasculitis in a nationwide, prospective, inception cohort study. Arthritis Res Ther. 2014; 16: R101.
- 31Ghosh P, Dwivedi S, Misra R, et al. Determining the prevalence of antineutrophil cytoplasmic antibody and the cut-offs of anti-PR3 and anti-MPO antibody in general population. Indian J Rheumatol. 2012; 7: 201-214.
10.1016/j.injr.2012.09.006 Google Scholar
- 32Sharma A, Lakshman A, Nampoothiri RV, et al. Pulmonary and Ear, Nose and Throat (ENT) involvement in ANCA-associated vasculitis at diagnosis- Experience from a tertiary care centre in North India. J Assoc Physicians India. 2017; 65: 40-47.
- 33Sharma A, Rajan R, Modi M, et al. Neurological manifestations do not affect cumulative survival in Indian patients with antineutrophil cytoplasmic antibody associated vasculitis. (Accepted for publication, Neurology India.)
- 34Sharma A, Gopalakrishan D, Nada R, et al. Uncommon presentations of primary systemic necrotizing vasculitides: the Great Masquerades. Int J Rheum Dis. 2014; 17: 562-572.
- 35Miloslavsky EM, Lu N, Unizony S, et al. Myeloperoxidase- Antineutrophil cytoplasmic antibody (ANCA)- positive and ANCA-negative patients with granulomatosis with polyangiitis (Wegener's): distinct patient subsets. Arthritis Rheumatol. 2016; 68: 2945-2952.
- 36Chen YX, Yu HJ, Zhang W, et al. Analyzing fatal cases of Chinese patients with primary antineutrophil cytoplasmic antibodies-associated renal vasculitis: a 10-year retrospective study. Kidney Blood Press Res. 2008; 31: 343-349.
- 37Chen M, Yu F, Zhang Y, et al. Clinical and pathological characteristics of Chinese patients with antineutrophil cytoplasmic autoantibody associated systemic vasculitides: a study of 426 patients from a single centre. Postgrad Med J. 2005; 81: 723-727.
- 38Sharma A, Kumar S, Wanchu A, et al. Successful treatment of hypertrophic pachymeningitis in refractory Wegener's granulomatosis with rituximab. Clin Rheumatol. 2010; 29: 107-110.
- 39Sen M, Dogra S, Rathi M, et al. Successful treatment of large refractory pyoderma gangrenosum-like presentation of granulomatosis with polyangiitis by rituximab. Int J Rheum Dis. 2017; 20: 2200-2202.
- 40Rathi M, Pinto B, Dhooria A, et al. Impact of renal involvement on survival in ANCA-associated vasculitis. Int Urol Nephrol. 2016; 48: 1477-1482.
- 41Naidu GS, Sharma A, Nada R, et al. Histopathological classification of pauci-immune glomerulonephritis and its impact on outcome. Rheumatol Int. 2014; 34: 1721-1727.
- 42Chang D, Wu L, Liu G, et al. Re-evaluation of the histopathological classification of ANCA-associated glomerulonephritis: a study of 121 patients in a single centre. Nephrol Dial Transplant. 2012; 27: 2343-2349.
- 43Iwakiri T, Fujimoto S, Kitagawa K, et al. Validation of a newly proposed histopathological classification in Japanese patients with anti-neutrophil cytoplasmic antibody-associated glomerulonephritis. BMC Nephrol. 2013; 14: 125.
- 44Sharma A, Nada R, Naidu GSRSNK, et al. Pauci-immune glomerulonephritis: does negativity of anti-neutrophil cytoplasmic antibodies matters? Int J Rheum Dis. 2016; 19: 74-81.